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The most common cause of acute kidney injury (AKI) in hospitalized patients is sepsis. However, the molecular
pathways and mechanisms that mediate septic AKI are not well defined. Experiments performed over the past
20 years suggest that there are profound differences in the pathogenesis between septic and ischemic AKI. Septic
AKI often occurs independently of hypoperfusion, and is mediated by a concomitant pro- and anti-inflammatory
state that is activated in response to various pathogen-associated molecular patterns, such as endotoxin, as well as
damage-associated molecular patterns. These molecular patterns are recognized by Toll-like receptors (TLRs) found
in the kidney, and effectuate downstream inflammatory pathways. Additionally, apoptosis has been proposed to
play a role in the pathogenesis of septic AKI. However, targeted therapies designed to mitigate the above aspects
of the inflammatory state, TLR-related pathways, and apoptosis have failed to show significant clinical benefit. This
failure is likely due to the protean nature of septic AKI, whereby different patients present at different points along
the immunologic spectrum. While one patient may benefit from targeted therapy at one end of the spectrum,
another patient at the other end may be harmed by the same therapy. We propose that a next important step in
septic AKI research will be to identify where patients lie on the immunologic spectrum in order to appropriately
target therapies at the inflammatory cascade, TLRs, and possibly apoptosis.Introduction
Acute kidney injury (AKI) is a very common and espe-
cially formidable clinical problem in the ICU, where
mortality rates approach 25% and soar to 50 to 60%
when severe enough to require renal replacement ther-
apy [1]. These statistics have not significantly improved
over the past 50 years, though patients today are gener-
ally older and have more comorbidities [1]. The most
common cause of AKI in hospitalized patients is sepsis
[2], and AKI occurs with regularity even in non-severe
sepsis where clinically evident hemodynamic changes
are not readily apparent [3]. The combination of sepsis
and AKI portends a dire clinical situation that is associated
with a hospital mortality rate as high as 70% [4]. However,
the basic pathophysiologic mechanisms undergirding the* Correspondence: pastorn@pitt.edu
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months following its publication. After this time
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medium, provided the original work is properly
(http://creativecommons.org/publicdomain/zeroassociation between sepsis and the clinical manifestations
of AKI are not completely understood.
In this review, we will first summarize the findings of
published human studies that support the concept that
the pathogenesis of septic AKI in humans should not be
exclusively viewed in the context of distributive shock-
associated ischemia, but rather also within the context
of a dysregulated and ill-defined inflammatory response
to septic stimuli. We then discuss why previous attempts
at modulating the inflammatory response in septic AKI
may have failed, and highlight more recent trials and
therapies aimed at targeted treatment based on where
patients lie along the immunologic spectrum. We also dis-
cuss the role Toll-like receptors (TLRs) have been shown
to play in endotoxemic models of AKI, and again focus on
why agents used to block TLR-related pathways may have
failed to show significant clinical benefit. Finally, we review
the data supporting and refuting a central role for apop-
tosis in septic AKI, and argue that much of the clinicalLtd. The licensee has exclusive rights to distribute this article, in any medium, for 12
, the article is available under the terms of the Creative Commons Attribution
y/4.0), which permits unrestricted use, distribution, and reproduction in any
credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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death secondary to apoptosis or necrosis.
Septic acute kidney injury: is it hyperemic kidney injury?
The morphologic changes that are seen in classic ischemic
and toxic acute tubular necrosis are often lacking [5,6] or
are microscopically distinct in septic AKI [7,8]. While the
use of renal biopsy in the management of septic AKI is
exceedingly rare in many western nations, most human
studies have found no consistent histopathologic changes
in septic AKI, and acute tubular necrosis is infrequently
observed [5,6]. In a systematic review of six studies
describing histopathologic changes seen in septic AKI,
Langenberg and colleagues [6] found that tubular epithe-
lial cell necrosis was seen in only 22% of human samples
taken after septic injury. A more recent study by Takasu
and colleagues [8] examined post-mortem kidneys taken
from 67 patients who died with sepsis, and while they
found focal tubular injury in 78% of septic kidneys, the
majority of tubular cells were normal.
Perhaps an even greater distinction between non-septic
AKI and septic AKI might be made when examining the
role of overall vascular hemodynamics. Traditionally, sep-
tic AKI has been thought to be secondary to a demand
and perfusion mismatch, whereby renal blood flow was
diminished in the midst of increased metabolic demand
[9,10]. Furthering this idea are the FINNAKI and SEPSIS-
PAM studies, two recently published trials that suggest
septic patients with target mean arterial pressure higher
than 65 mmHg might have less progression to AKI [11]
and less need for renal-replacement therapy if they suffer
from chronic hypertension [12].
Nevertheless, the data directly measuring overall kidney
blood flow during sepsis suggest that flow is increased in
the septic physiologic state. Despite a plethora of conflict-
ing animal studies - some of which show overall increased
kidney blood flow while others show overall decreased
kidney blood flow [10,13] - Langenberg and associates
[13] found only three human studies that have directly
measured renal blood flow in septic AKI by invasive
hemodynamic measurements. All three studies showed
that septic AKI occurs in the midst of renal arterial vaso-
dilation and preserved overall renal blood flow [14-16]. In
another study with a small cohort of 10 patients with
sepsis, renal blood flow was either preserved or in-
creased [17]. Bellomo and associates [18] have thus pro-
posed a new concept for understanding septic AKI
hemodynamics, so-called hyperemic AKI.
Despite the above human studies that suggest an
increase in overall renal blood flow in septic AKI, the
complex interplay between regional microcirculation
and hemodynamics may play a much more important
role in overall kidney function during sepsis. As Langen-
berg and colleagues [13] and Molitoris [19] point out,glomerular filtration rate (GFR) and cellular perfusion
can decrease even if overall renal blood flow is increased
due to disproportionate vascular resistance between the
afferent and efferent arterioles, regional microvascular
flow rates, or renal venous congestion. There are limited
human data regarding microcirculatory function in
septic AKI. However, using implanted laser Doppler flow
probes, Di Giantomasso and colleagues [20] showed that,
in sheep hyperdynamic septic models using Escherichia
coli infusion as a source of infection, regional redistri-
bution of blood flow from the medulla to the cortex was
absent during sepsis. Local inhibition of endothelial nitric
oxide synthase by liposaccharide (LPS) may play a role in
the decreased GFR observed in endotoxemic models of
AKI, at least in rats [21]. In a hyperdynamic endotoxemic
pig model, Cohen and associates [22] likewise observed a
significant increase in overall kidney blood flow after LPS
administration; however, almost all of the increased blood
flow was shunted to the medulla, with no increase in
cortical blood flow. In a sepsis pig model using peritonitis
as a source of infection, Chvojka and colleagues [23] ob-
served that while overall renal blood flow increased in
septic pigs with AKI, renal perfusion pressure significantly
decreased as a result of increased renal venous pressure.
In parallel to this, there was a significant decrease in renal
cortex microvascular perfusion as measured by laser
Doppler blood flow, as well as increased renal venous
acidosis and lactate concentrations [23]. These septic
physiologic observations related to regional kidney blood
flow have been found in humans as well. In a retrospective
observational study, it was shown that elevated central
venous pressure was associated with progression to AKI
in septic patients (odds ratio = 1.22, 95% confidence inter-
val (CI) 1.08 to 1.39), suggesting that venous congestion
may contribute to septic AKI in humans [24].
An in-depth discussion about renal microcirculation in
septic AKI is beyond the scope of this review. As men-
tioned above, there is a dearth of human data on this im-
portant topic and most of the animal data are conflicting
and difficult to interpret, given the different models used
and measurement modalities employed. While it is clear
from above that ischemic and microvascular dysfunction
may contribute to septic AKI, septic AKI can occur inde-
pendently of overall renal hypoperfusion or ischemia [25].
Indeed, AKI occurs in up to one-third of non-critically ill
patients with pneumonia, of which less than 10% received
any vasopressor therapy [3]. Additionally, there have been
many studies published over the past decade showing that
plasma and urinary biomarkers are often distinct in septic
and non-septic AKI (reviewed in [26]). This suggests a
fundamental mechanistic distinction that may involve
primarily a dysregulated immune response and possibly
apoptosis as opposed to ischemic factors related to distri-
butive shock [25].
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For many years, organ damage and other deleterious
sequelae from sepsis were thought to result from a
hyper-inflammatory ‘cytokine storm,’ triggered in response
to either an infectious pathogen or major physiologic
insult [27]. Thus, a significant amount of sepsis research
in the 1990s focused on identifying specific cytokines that
were associated with the stereotypical sepsis syndrome.
However, while cytokines such as TNF-α and IL-1β were
found in very high concentrations in septic patients, large
clinical trials testing specific cytokine inhibition failed to
show any clinical benefit [28,29].
As a consequence of these failed trails, new ideas regar-
ding the pathogenesis and pathophysiology of sepsis
emerged [30]. Utilizing pathologic data showing impaired
immune function in some septic patients, Hotchkiss and
Remick have both hypothesized that the host’s dysregu-
lated and ill-defined inflammatory response to stimuli is
associated with both pro- and anti-inflammatory states
[31-33]. Many septic patients are chronically ill, and their
development of sepsis is not necessarily associated with a
hyper-inflammatory response [31]. One current goal in
sepsis research is to identify where a septic patient lies on
the immunologic spectrum, and identify which patients
will benefit from specific therapies.
Indeed, the early trials focusing on inhibiting TNF-α
or IL-1β did not risk-stratify their patients in terms of
their individual inflammatory status or genetic predilec-
tions towards certain types of phenotypic responses
[28,29]. It seems likely that the next step in sepsis and
septic AKI treatment will be targeted therapy based on
stratification of patients that have a higher likelihood of
responding to various treatments. Panacek and colleagues
first attempted this strategy with a randomized controlled
trial to study afelimomab, an anti-TNF F(ab’)2 monoclonal
antibody fragment, in septic patients with and without
elevated serum levels of IL-6 [34]. In this study, for those
patients who had serum IL-6 levels >1,000 pg/mL, they
demonstrated a 4% absolute risk reduction in mortality at
28 days after treatment in patients treated with the agent
than in those not treated. Although rates of kidney failure
were not reported in this trial, there was a statistically
significant improvement in the overall Sequential Organ
Failure Assessment (SOFA) score starting at 48 hours after
drug administration.
As an alternative to targeted treatment, some resear-
chers have proposed implementing treatment strategies
that are able to broadly regulate the overall inflammatory
response in sepsis by using extra-corporeal blood purifica-
tion. Multiple in vitro and rat in vivo studies have demon-
strated that the broad reduction of inflammatory cytokines
by hemoadsorption can protect against renal and liver
injury [35], improve bacterial clearance [36] and mean
arterial pressure [37], decrease apoptosis and tubular celldamage [38], and improve overall survival [35,37]. How-
ever, its efficacy in humans is still unknown. The Early Use
of Polymyxin B Hemoperfusion in Abdominal Sepsis
(EUPHAS) trial showed improved hemodynamics, organ
function, and 28-day mortality in patients suffering from
severe sepsis or septic shock from intra-abdominal Gram-
negative infections who were treated with two sessions of
polymyxin B hemoperfusion compared with controls [39].
Renal SOFA scores improved in the treatment group (-0.3,
95% CI -0.7 to 0.1 versus 0.6, 95% CI 0.1 to 1.1) versus
control, as did overall cardiovascular function. However,
there were several methodological flaws in this small trial,
including a failure to measure endotoxin levels in the treat-
ment and control groups and the use of 28-day mortality
as a secondary endpoint. While these findings suggest
the need for larger clinical trials to be performed before
widespread implementation can be recommended, these
preliminary results appear promising.
Although the in vivo animal studies cited above have
shown that broad regulation of cytokine levels is possible
with the use of cytokine-reducing resins, modulation of
cytokine levels by continuous hemodialysis in humans
has not been clearly demonstrated. Despite the very short
half-life of many inflammatory cytokines, small initial
studies suggested that high-volume hemofiltration might
be able to modulate overall cytokine profiles in humans
[40,41]. However, larger randomized controlled trials
failed to show that continuous hemofiltration modulates
cytokine levels [42], nor has any clinical benefit been dem-
onstrated with the use of high-volume hemofiltration in
the treatment of sepsis [42-44]. While the large VA/NIH
Acute Renal Failure Trial Network study showed no mor-
tality difference in the septic subgroup of patients who
underwent more intense renal replacement, subsequent
analysis has shown higher rates of non-recovery of kidney
function and increased mortality in patients with higher
circulating concentrations of pro- and anti-inflammatory
cytokines and apoptosis markers [45]. This result again
suggests that targeting certain subgroups along the immu-
nologic spectrum might be beneficial not only in targeted
cytokine therapy, but also in the broad modulation of in-
flammatory cytokines via hemofiltration and absorption.
Finally, the use of agents to augment immune function
in patients suffering from sepsis-associated immunosup-
pression has shown clinical promise. As mentioned above,
sepsis represents a complex inflammatory state with both
pro- and anti-inflammatory characteristics. Thus, identify-
ing and treating septic patients who are on the more
immunosuppressed spectrum of sepsis with immune
augmentation may improve outcomes. Meisel and associ-
ates [46] administered granulocyte-macrophage colony-
stimulating factors (GM-CSFs) to septic patients who had
decreased monocyte HLA-DR expression and found that
monocyte immunocompetence could be restored in this
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clinical outcomes that were measured (ventilator days and
hospital length of stay), their data showed that biomarker-
guided GM-CSF therapy in sepsis is safe and could hold
promise in larger randomized controlled trials.
Toll-like receptor-4 and the effects of sepsis on renal
epithelial cells
Initial molecular research on sepsis suggested that the
generalized inflammatory state described above is ini-
tiated when the innate immune system recognizes highly
conserved pathogen-associated molecular patterns (PAMPs),
such as LPS [47]. However, in the late 1990s Polly Matzinger
[48] proposed the ‘danger model’, which argues that the
immune system is more concerned with ‘danger signals’
than with foreign signals. Subsequent research has
found that there are numerous ‘damage-associated mo-
lecular patterns’ (DAMPs) that can elicit immune re-
sponses similar to PAMPs [49]. The extent to which
both PAMPs (a subgroup of DAMPs) and more broadly
DAMPs activate the immune system and contribute to
sepsis and septic AKI is not fully understood, but recent
research has provided a significant amount of insight
into the process.
TLRs have provided a link between host and pathogen
[50,51], as well as host and DAMPs [52]. In the 1990s,
TLR-4 was found to be the main receptor that binds
LPS, leading to the release of TNF-α and IL-1 and
activation of numerous downstream intracellular signal-
ing pathways via the NF-κB transcription factor [50,53]
(Figure 1). Additionally, in sterile models of inflamma-
tion, TLR-4 has been shown to respond to DAMPs, such
as high mobility group-B1 [54-56]. Indeed, the capacity
of TLRs to respond to PAMPs as well as other DAMPs
provides a potential link between systemic inflammation
and kidney damage that is independent of ischemia and
hypotension. In the kidney, TLR-4 is constitutively ex-
pressed in mouse primary renal tubular epithelial cells
[57] and in mouse cells harvested from in vivo experi-
ments [58], in renal tubular cells harvested from rats
[59,60], and in human kidney tubular epithelial cells taken
from surgical patients [61]. TLR-4 expression in the
glomeruli is controversial [59,60], but its expression
in tubular epithelial cells has been shown to modulate
septic AKI and inflammation (Figure 1) in multiple
models of injury [60,62,63]. The final downstream
mechanisms that produce AKI after TLR-4 activation
are complex and incompletely understood. Of note,
recent work suggests that one important mechanism
underpinning septic AKI is that this inflammatory path-
way induces renal tubular transport dysfunction,
which enhances NaCl delivery to the macula densa
and increases tubuloglomerular feedback, thus decreasing
GFR [64].NF-κB is a highly expressed transcription factor that is
often activated in response to cellular stresses and
induces the synthesis and release of TNF-α, IL-1, IL-6,
and IL-8 [65]. NF-κB-mediated processes occur in iso-
lated primary rat proximal tubular epithelial cells [66],
but the overall contribution of inflammatory cytokine
levels in the kidney from local versus systemic produc-
tion of those cytokines is unknown. Experiments per-
formed on TLR-4 knockout mice transplanted with
TLR-4 expressing kidneys suggest systemic production
may be more important [62]. Direct inhibition of NF-κB
with agents such as methyl-2-acetamidoacrylate (an ethyl
pyruvate analogue) [67], ethyl pyruvate [68], and nico-
tinic acetylcholine [69] can lower cytokine levels in mice
(TNF-α, IL-6, IFN-γ, and IL-10) and have been associated
with improved clinical characteristics in mice suffering
from septic AKI [67-69].
However, a recent randomized controlled trial examin-
ing the effect of an MD2-TLR-4 antagonist failed to
show any mortality benefit in human patients suffering
from severe sepsis [70]. In this study, none of the patients
enrolled were stratified in terms of what type of infection
they were suffering from (polymicrobial, Gram-positive,
or Gram-negative). Moreover, levels of endotoxin were
not measured, which leaves open the possibility that some
patients may have benefited depending on where they
stood on the immunologic spectrum. Nonetheless, this
trial possibly highlights some of the pitfalls of associating
LPS endotoxemia with human sepsis that have manifested
themselves over the past 20 years in sepsis research.
Indeed, multiple studies have shown that in polymicro-
bial and cecal ligation and puncture models the mechan-
ism of damage induced by sepsis may be very different
than in LPS-induced models [71], might be independent
of TLRs altogether [72-75], and instead could be mediated
by direct MyD88 regulation (Figure 1) [72,75]. Interest-
ingly, the presence of a specific TLR-4 mutation (D299G)
in humans, which impairs LPS signaling, has not been
shown to influence TNF-α, IL-6, and IL-10 levels in sepsis
[73]. Nor has this particular allele been associated with
any change in outcome or development of sepsis in
patients undergoing major visceral surgery [73] or in pa-
tients with meningococcal disease [76]. The effect of this
specific mutation has not been examined in kidneys dir-
ectly, and its study may provide significant insight into the
mechanisms of septic AKI in humans. Of note, the use of
various mouse models to study human inflammation
and sepsis has recently been questioned due to the
significant differences in the two species’ genomic re-
sponses to stress [77].
Does apoptosis have a role in septic acute kidney injury?
The traditional model of apoptosis in kidney and other
cells is similar [78]. Processes involving the mitochondria
Figure 1 Schematic illustration of the activation of the NF-κB transcription factor pathway by liposaccharide (LPS), TNF-α, high mobility
group (HMG)B1, and polymicrobial sepsis. LPS binding to Toll-like receptor-4 (TLR-4) is dependent on its interaction with circulating LPS-binding
protein (LBP) and the subsequent interplay of this complex to membrane bound CD14 [90]. This LPS-LBP-CD14-TLR-4 complex is thus anchored to
various cells within the kidney (especially within the apical brush border of proximal tubules) [60], where it initiates intracellular signaling cascades.
CD14 gene expression is upregulated by LPS [91] in human kidney proximal tubular epithelial cells and by TNF-α [92] in mouse renal interstitial and
tubular epithelial cells. Activated TLR-4 via LPS stimulates the MyD88 pathway [47,93,94], and ultimately induces phosphorylation of IκB by IκB-kinase-β
(IKKβ; tan-colored) within the IKK complex [65]. Phosphorylated IκB is then released from NF-κB, allowing NF-κB to migrate to the nucleus to modulate
transcription of various cytokines as shown. HMGB1 activation of TLR-4 activates NF-κB via an alternative mechanism whereby both IKKα and IKKβ
(tan-colored) are implicated [54,55]. In cecal ligation and puncture models of sepsis, MyD88 has been shown to be activated independent of TLR-4 by
unknown upstream cell surface receptors [72,75]. IRAK, interleukin receptor-associated kinase; MAPK, p38 mitogen-activated protein kinase; TRAF,
TNF receptor associated factor.
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cell surface proteins leading to subsequent intracellular
signaling events are termed ‘extrinsic’ processes (Figure 2)
[78]. However, the mechanisms whereby cells in the septic
kidney succumb (or do not succumb) to apoptosis are still
under investigation. One important route may be via
the tumor necrosis factor receptor-1 (TNFR-1; Figure 2).
TNFR-1 knockout mice were resistant to LPS-induced
kidney failure while they also manifested much less apop-
tosis and neutrophil accumulation, suggesting a direct role
for both necrosis and apoptosis in septic AKI [79]. Down-
stream of TNFR-1, Jo and colleagues [80] have shown that
apoptosis in LPS, TNF-α, and IL-1 exposed HK-2 cells islikely dependent in part on Fas and caspase expression.
Caspase inhibition has also been shown to prevent apop-
totic proximal, distal, and peri-tubular cell death in LPS
models of septic AKI [81]. Cantaluppi and associates
[38] have demonstrated a role for the Fas and caspase-
mediated pathway in septic AKI as well. Using primary
human proximal tubule epithelial cells exposed to septic
human plasma, they showed that: 1) apoptosis as detected
through DNA TUNEL assays was significantly increased
in cells exposed to septic plasma; 2) levels of Fas and
caspase-3, -8, and -9 were all significantly increased in
response to septic plasma; and 3) levels of those effector
signals and apoptosis can be decreased by removal of
Figure 2 Schematic illustration of the molecular processes leading to apoptosis in renal proximal tubular epithelial cells. So-called death
receptors such as Fas, TNF receptor-1 (TNFR-1), or the TNF-related apoptosis-inducing ligand (TRAIL) receptors bind with extracellular ligands to
activate downstream activator caspases [78]. This process is usually mediated by the FADD (Fas-associated protein with death domain) receptor,
and ultimately activates caspase-3 - the effector molecule. Within the cell, the intrinsic pathway is initiated via cellular stresses: reactive oxygen
species (ROS), nitric oxide, decreased ATP, or cell-cell/cell-matrix perturbations [95]. In response to those stresses, BAX migrates into the mitochondria
via activation from BH3-only proteins within the Bcl-2 family [96]. Once they have entered the mitochondria, BAX and other pro-apoptotic proteins form
pores within the mitochondrial wall, allowing for the release of cytochrome c, which triggers caspase-dependent and -independent pathways [95].
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filter septic plasma [38]. Indeed, initiation of apoptosis
was observed in cultured kidney tubular cells exposed to
plasma taken from patients suffering from severe burns
and septic AKI [82].
However, in most of the in vitro and in vivo studies
examining the presence or role of apoptosis in septic
AKI, there were major methodological shortcomings.
LPS was used as a model for sepsis in most of the studies
cited above [79-81], as well as many experiments evaluat-
ing kidney tubular apoptosis in primary mouse distal
convoluted tubule cells [83] and mouse MCT proximal
tubule cells [84]. As mentioned in the previous section,
LPS endotoxemia is not a model of sepsis. Perhaps even
more confounding to the argument that apoptosis is a
major factor in septic AKI is the lack of histological evi-
dence in patients with septic AKI. Histologic sections of
septic human kidneys generally demonstrate very little
necrosis or cell damage [5-8]. Moreover, a significant
amount of data taken from ‘warm’ autopsies [5,8] has alsofailed to show substantial apoptosis, at least as measured
by conventional light microscopy [5], electron microscopy
[8], and DNA agarose gel electrophoresis for apoptotic
laddering [5]. In the seminal septic autopsy study perfor-
med by Hotchkiss and colleagues [5], they failed to ob-
serve any evidence of kidney apoptosis despite the fact
that 65% of their samples were taken from patients with
clinically manifest sepsis-associated kidney dysfunction.
While apoptosis likely plays a major role in lymphocytes
and other cells within the human body during sepsis [30],
its role in septic AKI is unclear. Further study using more
physiologically relevant models of sepsis (as opposed to
LPS) are needed to help reconcile much of the conflicting
data that currently exist.
Perhaps one of the reasons for the discrepancy between
histologic data and functional performance in septic AKI
is that most of the insults occur prior to significant cell
death from apoptosis and necrosis. Indeed, apoptosis and
necrosis are end-stage manifestations of cellular insults,
and significant impairment of cellular function can occur
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sured in most apoptosis and necrosis assays. Despite a
measured decrease in kidney perfusion in their septic
mouse model, Tran and associates found no elevation in
hypoxia-inducible factor-1α, a transcription factor that is
significantly upregulated [85] in hypoxic and ischemic rat
kidneys [86]. They hypothesized that this was due to
significantly reduced oxygen consumption by kidney
proximal tubule cells during sepsis [86]. Further study
showed that this process was likely mediated by PPARγ
coactivator-1α (PGC-1α), a major regulator of mitochon-
drial function. PGC-1α was significantly downregulated in
septic rats exposed to LPS and TNF-α, whereas increased
levels of PGC-1α were associated with restored oxygen
consumption and improved kidney function [86]. While
increased expression of hypoxia-inducible factor-1α was
not seen in mice exposed to LPS [86], sepsis has been
associated with significant intra-renal oxidative and nitro-
sative stress that is mediated by inflammatory cytokines
rather than local hypoxia or ischemia [87,88]. The idea of
‘cellular stunning’, whereby a cell that is living within a
septic environment is trying to defend itself from death by
decreasing its metabolic activity, has been proposed as a
mechanism not only in sepsis by Hotchkiss and Karl [30],
but also in ischemic models in the heart [89].
Conclusion
While the relative contributions that ischemia, TLR-4-
mediated pathways, apoptosis, and other subcellular
processes have towards overall organ dysfunction are
currently unclear, the abundance of research in the area
has shed a significant amount of light on the basic mecha-
nisms that drive septic AKI. Perhaps the most important
finding is that therapeutic approaches targeted at a single
mediator for all patients may not succeed given the pro-
tean nature of the disease. Indeed, targeted inhibition of
cytokines such as TNF-α and IL-1 as well as TLR antago-
nists have failed to show consistent and significant clinical
benefit, most likely because only certain subsets of septic
patients fit an immunologic profile that would benefit
from those therapies. An important next step in sepsis
research should be to identify immunologic markers in
patients that can help tailor specific therapies for patients
based on where they lie along the immunologic spectrum.
Abbreviations
AKI: Acute kidney injury; CI: Confidence interval; DAMP: Damage-associated
molecular pattern; GFR: Glomerular filtration rate; GM-CSF: Granulocyte-
macrophage colony-stimulating factor; IFN: Interferon; IL: Interleukin;
LPS: Lipopolysaccharide; NF: Nuclear factor; PAMP: Pathogen-associated
molecular pattern; PGC-1α: PPARγ coactivator-1α; SOFA: Sequential Organ
Failure Assessment; TLR: Toll-like receptor; TNF: Tumor necrosis factor;
TNFR: Tumor necrosis factor receptor.
Competing interests
The authors declare that they have no competing interests.Acknowledgements
Work performed in our laboratories and the preparation of this review were
supported by grants from the National institutes of Health: P30 DK079307
to NMPS and KRH, R01 DK084184 to NMPS, the University of Pittsburgh,
Department of Medicine Junior Scholar Awards to NMPS, R01 DK075048 to
KRH, R01 HL080926 to JAK, and R01 DK070910 to JAK.
Author details
1Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh
School of Medicine, Pittsburgh, PA 15261, USA. 2The Center for Critical Care
Nephrology, University of Pittsburgh School of Medicine, Pittsburgh, PA
15261, USA. 3CRISMA (Clinical Research Systems Modeling of Acute Illness)
Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261,
USA. 4Department of Critical Care Medicine, University of Pittsburgh School
of Medicine, Pittsburgh, PA 15261, USA. 5Department of Cell Biology,
University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
References
1. Ympa YP, Sakr Y, Reinhart K, Vincent JL: Has mortality from acute renal
failure decreased? A systematic review of the literature. Am J Med 2005,
118:827–832.
2. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz
M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C, Beginning
and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators:
Acute renal failure in critically ill patients: a multinational, multicenter
study. JAMA 2005, 294:813–818.
3. Murugan R, Karajala-Subramanyam V, Lee M, Yende S, Kong L, Carter M,
Angus DC, Kellum JA: Acute kidney injury in non-severe pneumonia is
associated with an increased immune response and lower survival.
Kidney Int 2010, 77:527–535.
4. Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I,
Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten HM,
Ronco C, Kellum JA, Beginning and Ending Supportive Therapy for the
Kidney (BEST Kidney) Investigators: Septic acute kidney injury in critically
ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol
2007, 2:431–439.
5. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak
GM, Buchman TG, Karl IE: Apoptotic cell death in patients with sepsis,
shock, and multiple organ dysfunction. Crit Care Med 1999, 27:1230–1251.
6. Langenberg C, Bagshaw SM, May CN, Bellomo R: The histopathology of
septic acute kidney injury: a systematic review. Crit Care 2008, 12:R38.
7. Lerolle N, Nochy D, Guerot E, Bruneval P, Fagon JY, Diehl JL, Hill G:
Histopathology of septic shock induced acute kidney injury: apoptosis
and leukocytic infiltration. Intensive Care Med 2010, 36:471–478.
8. Takasu O, Gaut JP, Watanabe E, To K, Fagley RE, Sato B, Jarman S, Efimov IR,
Janks DL, Srivastava A, Bhayani SB, Drewry A, Swanson PE, Hotchkiss RS:
Mechanisms of cardiac and renal dysfunction in patients dying of sepsis.
Am J Respir Crit Care Med 2013, 187:509–517.
9. Schrier RW, Wang W, Poole B, Mitra A: Acute renal failure: definitions,
diagnosis, pathogenesis, and therapy. J Clin Invest 2004, 114:5–14.
10. Bougle A, Duranteau J: Pathophysiology of sepsis-induced acute kidney
injury: the role of global renal blood flow and renal vascular resistance.
Contrib Nephrol 2011, 174:89–97.
11. Poukkanen M, Wilkman E, Vaara ST, Pettilä V, Kaukonen KM, Korhonen AM,
Uusaro A, Hovilehto S, Inkinen O, Laru-Sompa R, Hautamäki R, Kuitunen A,
Karlsson S, the FINNAKI Study Group: Hemodynamic variables and
progression of acute kidney injury in critically ill patients with severe
sepsis: data from the prospective observational FINNAKI study. Crit Care
2013, 17:R295.
12. Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N, Mira JP,
Dequin PF, Gergaud S, Weiss N, Legay F, Le Tulzo Y, Conrad M, Robert R,
Gonzalez F, Guitton C, Tamion F, Tonnelier JM, Guezennec P, Van Der
Linden T, Vieillard-Baron A, Mariotte E, Pradel G, Lesieur O, Ricard JD,
Hervé F, du Cheyron D, Guerin C, Mercat A, Teboul JL, et al: High versus
low blood-pressure target in patients with septic shock. N Engl J Med
2014, 370:1583–1593.
13. Langenberg C, Bellomo R, May C, Wan L, Egi M, Morgera S: Renal blood
flow in sepsis. Crit Care 2005, 9:R363–R374.
Morrell et al. Critical Care 2014, 18:501 Page 8 of 10
http://ccforum.com/content/18/4/50114. Brenner M, Schaer GL, Mallory DL, Suffredini AF, Parrillo JE: Detection of
renal blood flow abnormalities in septic and critically ill patients using a
newly designed indwelling thermodilution renal vein catheter.
Chest 1990, 98:170–179.
15. Lucas CE, Rector FE, Werner M, Rosenberg IK: Altered renal homeostasis
with acute sepsis. Clinical significance. Arch Surg 1973, 106:444–449.
16. Rector F, Goyal S, Rosenberg IK, Lucas CE: Sepsis: a mechanism for
vasodilatation in the kidney. Ann Surg 1973, 178:222–226.
17. Bradley VE, Shier MR, Lucas CE, Rosenberg IK: Renal hemodynamic
response to furosemide in septic and injured patients. Surgery 1976,
79:549–554.
18. Wan L, Bagshaw SM, Langenberg C, Saotome T, May C, Bellomo R:
Pathophysiology of septic acute kidney injury: what do we really know?
Crit Care Med 2008, 36:S198–S203.
19. Molitoris BA: Renal blood flow in sepsis: a complex issue. Crit Care 2005,
9:327–328.
20. Di Giantomasso D, Morimatsu H, May CN, Bellomo R: Intrarenal blood flow
distribution in hyperdynamic septic shock: effect of norepinephrine.
Crit Care Med 2003, 31:2509–2513.
21. Schwartz D, Mendonca M, Schwartz I, Xia Y, Satriano J, Wilson CB,
Blantz RC: Inhibition of constitutive nitric oxide synthase (NOS)
by nitric oxide generated by inducible NOS after lipopolysaccharide
administration provokes renal dysfunction in rats. J Clin Invest 1997,
100:439–448.
22. Cohen RI, Hassell AM, Marzouk K, Marini C, Liu SF, Scharf SM: Renal
effects of nitric oxide in endotoxemia. Am J Respir Crit Care Med 2001,
164:1890–1895.
23. Chvojka J, Sykora R, Krouzecky A, Radej J, Varnerova V, Karvunidis T, Hes O,
Novak I, Radermacher P, Matejovic M: Renal haemodynamic,
microcirculatory, metabolic and histopathological responses to
peritonitis-induced septic shock in pigs. Crit Care 2008, 12:R164.
24. Legrand M, Dupuis C, Simon C, Gayat E, Mateo J, Lukaszewicz AC, Payen D:
Association between systemic hemodynamics and septic acute kidney
injury in critically ill patients: a retrospective observational study.
Crit Care 2013, 17:R278.
25. Kellum JA: Impaired renal blood flow and the ‘spicy food’ hypothesis of
acute kidney injury. Crit Care Med 2011, 39:901–903.
26. Zarjou A, Agarwal A: Sepsis and acute kidney injury. J Am Soc Nephrol
2011, 22:999–1006.
27. Thomas L: Germs. N Engl J Med 1972, 287:553–555.
28. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E,
Schein RM, Benjamin E: Treatment of septic shock with the tumor
necrosis factor receptor:Fc fusion protein, The Soluble TNF Receptor
Sepsis Study Group. N Engl J Med 1996, 334:1697–1702.
29. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ,
Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson BW,
LaBrecque JF, Catalano MA, Knaus WA, Sadoff JC, Astiz M, Carpati C, Bone
RC, Friedman B, Mure AJ, Brathwaite C, Shapiro E, Melhorn L, Taylor R,
Keegan M, O’Brien J, Schein R, Pena M, et al: Recombinant human
interleukin 1 receptor antagonist in the treatment of patients with
sepsis syndrome. Results from a randomized, double-blind,
placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.
JAMA 1994, 271:1836–1843.
30. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl
J Med 2003, 348:138–150.
31. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL,
Jarman SD 2nd, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM,
Hotchkiss RS: Immunosuppression in patients who die of sepsis and
multiple organ failure. JAMA 2011, 306:2594–2605.
32. Osuchowski MF, Welch K, Siddiqui J, Remick DG: Circulating cytokine/
inhibitor profiles reshape the understanding of the SIRS/CARS
continuum in sepsis and predict mortality. J Immunol 2006,
177:1967–1974.
33. Hotchkiss RS, Monneret G, Payen D: Immunosuppression in sepsis: a novel
understanding of the disorder and a new therapeutic approach.
Lancet Infect Dis 2013, 13:260–268.
34. Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur
RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, Teoh L, Van Meter L,
Daum L, Lemeshow S, Hicklin G, Doig C, Monoclonal Anti-TNF-a
Randomized Controlled Sepsis Study Investigators: Efficacy and safety of
the monoclonal anti-tumor necrosis factor antibody F(ab’)2 fragmentafelimomab in patients with severe sepsis and elevated interleukin-6
levels. Crit Care Med 2004, 32:2173–2182.
35. Peng ZY, Wang HZ, Carter MJ, Dileo MV, Bishop JV, Zhou FH, Wen XY,
Rimmelé T, Singbartl K, Federspiel WJ, Clermont G, Kellum JA: Acute
removal of common sepsis mediators does not explain the effects of
extracorporeal blood purification in experimental sepsis. Kidney Int 2012,
81:363–369.
36. Namas RA, Namas R, Lagoa C, Barclay D, Mi Q, Zamora R, Peng Z, Wen X,
Fedorchak MV, Valenti IE, Federspiel WJ, Kellum JA, Vodovotz Y:
Hemoadsorption reprograms inflammation in experimental gram-negative
septic peritonitis: insights from in vivo and in silico studies. Mol Med 2012,
18:1366–1374.
37. Peng ZY, Carter MJ, Kellum JA: Effects of hemoadsorption on cytokine
removal and short-term survival in septic rats. Crit Care Med 2008,
36:1573–1577.
38. Cantaluppi V, Weber V, Lauritano C, Figliolini F, Beltramo S, Biancone L,
De Cal M, Cruz D, Ronco C, Segoloni GP, Tetta C, Camussi G: Protective
effect of resin adsorption on septic plasma-induced tubular injury.
Crit Care 2010, 14:R4.
39. Cruz DN1, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A,
Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F,
Ronco C: Early use of polymyxin B hemoperfusion in abdominal
septic shock: the EUPHAS randomized controlled trial. JAMA 2009,
301:2445–2452.
40. De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter JH,
Lameire NH: Cytokine removal during continuous hemofiltration in septic
patients. J Am Soc Nephrol 1999, 10:846–853.
41. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P:
High-volume haemofiltration in human septic shock. Intensive Care Med
2001, 27:978–986.
42. Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E: Impact of
continuous venovenous hemofiltration on organ failure during the early
phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009,
37:803–810.
43. Joannes-Boyau O, Honoré PM, Perez P, Bagshaw SM, Grand H, Canivet JL,
Dewitte A, Flamens C, Pujol W, Grandoulier AS, Fleureau C, Jacobs R, Broux
C, Floch H, Branchard O, Franck S, Rozé H, Collin V, Boer W, Calderon J,
Gauche B, Spapen HD, Janvier G, Ouattara A: High-volume versus
standard-volume haemofiltration for septic shock patients with acute
kidney injury (IVOIRE study): a multicentre randomized controlled trial.
Intensive Care Med 2013, 39:1535–1546.
44. VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, O’Connor
TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E,
Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S,
Star RA, Peduzzi P: Intensity of renal support in critically ill patients with
acute kidney injury. N Engl J Med 2008, 359:7–20.
45. Wen X, Murugan R, Kong L, Shah N, Lee MJ, Carter MJ, Elder MM, Palevsky
PM, Unruh ML, Kellum JA: Higher concentrations of inflammatory and
apoptotic biomarkers are associated with mortality and nonrecovery of
kidney function. J Am Soc Nephrol 2011, 22:83A.
46. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J,
Weber-Carstens S, Hasper D, Keh D, Zuckermann H, Reinke P, Volk HD:
Granulocyte-macrophage colony-stimulating factor to reverse
sepsis-associated immunosuppression: a double-blind, randomized,
placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009,
180:640–648.
47. Cohen J: The immunopathogenesis of sepsis. Nature 2002, 420:885–891.
48. Matzinger P: The danger model: a renewed sense of self. Science 2002,
296:301–305.
49. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K,
Hauser CJ: Circulating mitochondrial DAMPs cause inflammatory
responses to injury. Nature 2010, 464:104–107.
50. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E,
Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler
B: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations
in Tlr4 gene. Science 1998, 282:2085–2088.
51. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr: A human homologue of
the Drosophila Toll protein signals activation of adaptive immunity.
Nature 1997, 388:394–397.
52. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A: HMGB1: endogenous
danger signaling. Mol Med 2008, 14:476–484.
Morrell et al. Critical Care 2014, 18:501 Page 9 of 10
http://ccforum.com/content/18/4/50153. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F: Toll-like
receptor-4 mediates lipopolysaccharide-induced signal transduction.
J Biol Chem 1999, 274:10689–10692.
54. Park JS, Arcaroli J, Yum HK, Yang H, Wang H, Yang KY, Choe KH,
Strassheim D, Pitts TM, Tracey KJ, Abraham E: Activation of gene
expression in human neutrophils by high mobility group box 1 protein.
Am J Physiol Cell Physiol 2003, 284:C870–C879.
55. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E:
Involvement of toll-like receptors 2 and 4 in cellular activation by high
mobility group box 1 protein. J Biol Chem 2004, 279:7370–7377.
56. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D,
Sohn JW, Yamada S, Maruyama I, Banerjee A, Ishizaka A, Abraham E: High
mobility group box 1 protein interacts with multiple Toll-like receptors.
Am J Physiol Cell Physiol 2006, 290:C917–C924.
57. Tsuboi N, Yoshikai Y, Matsuo S, Kikuchi T, Iwami K, Nagai Y, Takeuchi O,
Akira S, Matsuguchi T: Roles of toll-like receptors in C-C chemokine
production by renal tubular epithelial cells. J Immunol 2002,
169:2026–2033.
58. Wolfs TG, Buurman WA, van Schadewijk A, de Vries B, Daemen MA,
Hiemstra PS, va Veer C: In vivo expression of Toll-like receptor 2 and 4 by
renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation
during inflammation. J Immunol 2002, 168:1286–1293.
59. Laestadius A, Soderblom T, Aperia A, Richter-Dahlfors A: Developmental
aspects of Escherichia coli-induced innate responses in rat renal
epithelial cells. Pediatric Res 2003, 54:536–541.
60. El-Achkar TM, Huang X, Plotkin Z, Sandoval RM, Rhodes GJ, Dagher PC:
Sepsis induces changes in the expression and distribution of Toll-like
receptor 4 in the rat kidney. Am J Physiol Renal Physiol 2006,
290:F1034–F1043.
61. Samuelsson P, Hang L, Wullt B, Irjala H, Svanborg C: Toll-like receptor 4
expression and cytokine responses in the human urinary tract mucosa.
Infect Immun 2004, 72:3179–3186.
62. Cunningham PN, Wang Y, Guo R, He G, Quigg RJ: Role of Toll-like
receptor 4 in endotoxin-induced acute renal failure. J Immunol 2004,
172:2629–2635.
63. Patole PS, Schubert S, Hildinger K, Khandoga S, Khandoga A, Segerer S,
Henger A, Kretzler M, Werner M, Krombach F, Schlöndorff D, Anders HJ:
Toll-like receptor-4: renal cells and bone marrow cells signal for
neutrophil recruitment during pyelonephritis. Kidney Int 2005,
68:2582–2587.
64. Morrell ED, Kellum JA, Hallows KR, Pastor-Soler NM: Epithelial transport
during septic acute kidney injury. Nephrol Dial Transplant 2014,
29:1312–1319.
65. Senftleben U, Karin M: The IKK/NF-kappa B pathway. Crit Care Med 2002,
30:S18–S26.
66. Wang Y, Rangan GK, Goodwin B, Tay YC, Harris DC: Lipopolysaccharide-
induced MCP-1 gene expression in rat tubular epithelial cells is nuclear
factor-kappaB dependent. Kidney Int 2000, 57:2011–2022.
67. Leelahavanichkul A, Yasuda H, Doi K, Hu X, Zhou H, Yuen PS, Star RA:
Methyl-2-acetamidoacrylate, an ethyl pyruvate analog, decreases
sepsis-induced acute kidney injury in mice. Am J Physiol Renal Physiol
2008, 295:F1825–F1835.
68. Miyaji T, Hu X, Yuen PS, Muramatsu Y, Iyer S, Hewitt SM, Star RA: Ethyl
pyruvate decreases sepsis-induced acute renal failure and multiple
organ damage in aged mice. Kidney Int 2003, 64:1620–1631.
69. Chatterjee PK, Yeboah MM, Dowling O, Xue X, Powell SR, Al-Abed Y,
Metz CN: Nicotinic acetylcholine receptor agonists attenuate septic acute
kidney injury in mice by suppressing inflammation and proteasome
activity. PLoS One 2012, 7:e35361.
70. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X,
Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T,
Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R,
Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler
JL, Vincent JL, ACCESS Study Group: Effect of eritoran, an antagonist of
MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS
randomized trial. JAMA 2013, 309:1154–1162.
71. Remick DG, Newcomb DE, Bolgos GL, Call DR: Comparison of the mortality
and inflammatory response of two models of sepsis: lipopolysaccharide
versus cecal ligation and puncture. Shock 2000, 13:110–116.
72. Dear JW, Yasuda H, Hu X, Hieny S, Yuen PS, Hewitt SM, Sher A, Star RA:
Sepsis-induced organ failure is mediated by different pathways in thekidney and liver: acute renal failure is dependent on MyD88 but not
renal cell apoptosis. Kidney Int 2006, 69:832–836.
73. Feterowski C, Emmanuilidis K, Miethke T, Gerauer K, Rump M, Ulm K,
Holzmann B, Weighardt H: Effects of functional Toll-like receptor-4
mutations on the immune response to human and experimental sepsis.
Immunology 2003, 109:426–431.
74. McMasters KM, Peyton JC, Hadjiminas DJ, Cheadle WG: Endotoxin and
tumour necrosis factor do not cause mortality from caecal ligation and
puncture. Cytokine 1994, 6:530–536.
75. Weighardt H, Kaiser-Moore S, Vabulas RM, Kirschning CJ, Wagner H,
Holzmann B: Cutting edge: myeloid differentiation factor 88 deficiency
improves resistance against sepsis caused by polymicrobial infection.
J Immunol 2002, 169:2823–2827.
76. Read RC, Pullin J, Gregory S, Borrow R, Kaczmarski EB, di Giovine FS,
Dower SK, Cannings C, Wilson AG: A functional polymorphism of toll-like
receptor 4 is not associated with likelihood or severity of meningococcal
disease. J Infect Dis 2001, 184:640–642.
77. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR,
McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, López CM, Honari S,
Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB,
Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein
BH, Miller-Graziano C, Calvano SE, Mason PH, et al: Genomic responses in
mouse models poorly mimic human inflammatory diseases. Proc Natl
Acad Sci U S A 2013, 110:3507–3512.
78. Havasi A, Borkan SC: Apoptosis and acute kidney injury. Kidney Int 2011,
80:29–40.
79. Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ: Acute
renal failure in endotoxemia is caused by TNF acting directly on TNF
receptor-1 in kidney. J Immunol 2002, 168:5817–5823.
80. Jo SK, Cha DR, Cho WY, Kim HK, Chang KH, Yun SY, Won NH: Inflammatory
cytokines and lipopolysaccharide induce Fas-mediated apoptosis in renal
tubular cells. Nephron 2002, 91:406–415.
81. Guo R, Wang Y, Minto AW, Quigg RJ, Cunningham PN: Acute renal failure
in endotoxemia is dependent on caspase activation. J Am Soc Nephrol
2004, 15:3093–3102.
82. Mariano F, Cantaluppi V, Stella M, Romanazzi GM, Assenzio B, Cairo M,
Biancone L, Triolo G, Ranieri VM, Camussi G: Circulating plasma factors
induce tubular and glomerular alterations in septic burns patients.
Crit Care 2008, 12:R42.
83. Duranton C, Rubera I, L’Hoste S, Cougnon M, Poujeol P, Barhanin J,
Tauc M: KCNQ1 K + channels are involved in lipopolysaccharide-induced
apoptosis of distal kidney cells. Cell Physiol Biochem 2010,
25:367–378.
84. Ortiz-Arduan A, Danoff TM, Kalluri R, Gonzalez-Cuadrado S, Karp SL,
Elkon K, Egido J, Neilson EG: Regulation of Fas and Fas ligand expression
in cultured murine renal cells and in the kidney during endotoxemia.
Am J Physiol 1996, 271:F1193–F1201.
85. Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS,
Horstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S,
Eckardt KU: Expression of hypoxia-inducible factor-1alpha and -2alpha
in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002,
13:1721–1732.
86. Tran M, Tam D, Bardia A, Bhasin M, Rowe GC, Kher A, Zsengeller ZK,
Akhavan-Sharif MR, Khankin EV, Saintgeniez M, David S, Burstein D,
Karumanchi SA, Stillman IE, Arany Z, Parikh SM: PGC-1alpha promotes
recovery after acute kidney injury during systemic inflammation in mice.
J Clin Invest 2011, 121:4003–4014.
87. Huet O, Cherreau C, Nicco C, Dupic L, Conti M, Borderie D, Pene F, Vicaut E,
Benhamou D, Mira JP, Duranteau J, Batteux F: Pivotal role of glutathione
depletion in plasma-induced endothelial oxidative stress during sepsis.
Crit Care Med 2008, 36:2328–2334.
88. Heyman SN, Rosen S, Rosenberger C: A role for oxidative stress.
Contrib Nephrol 2011, 174:138–148.
89. Sawyer DB, Loscalzo J: Myocardial hibernation: restorative or preterminal
sleep? Circulation 2002, 105:1517–1519.
90. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor
for complexes of lipopolysaccharide (LPS) and LPS binding protein.
Science 1990, 249:1431–1433.
91. Bussolati B, David S, Cambi V, Tobias PS, Camussi G: Urinary soluble CD14
mediates human proximal tubular epithelial cell injury induced by LPS.
Int J Mol Med 2002, 10:441–449.
Morrell et al. Critical Care 2014, 18:501 Page 10 of 10
http://ccforum.com/content/18/4/50192. Fearns C, Loskutoff DJ: Role of tumor necrosis factor alpha in induction of
murine CD14 gene expression by lipopolysaccharide. Infect Immun 1997,
65:4822–4831.
93. El-Achkar TM, Dagher PC: Renal Toll-like receptors: recent advances and
implications for disease. Nat Clin Pract Nephrol 2006, 2:568–581.
94. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S,
Janeway CA Jr: MyD88 is an adaptor protein in the hToll/IL-1 receptor
family signaling pathways. Mol Cell 1998, 2:253–258.
95. Taal MW, Brenner BM, Rector FC: Brenner & Rector’s the Kidney. 9th edition.
Philadelphia, PA: Elsevier/Saunders; 2012.
96. Green DR, Kroemer G: The pathophysiology of mitochondrial cell death.
Science 2004, 305:626–629.
doi:10.1186/s13054-014-0501-5
Cite this article as: Morrell et al.: Septic acute kidney injury: molecular
mechanisms and the importance of stratification and targeting therapy.
Critical Care 2014 18:501.
